Lupin stock closes 7% higher post US FDA clearance

BT Online        Last Updated: November 7, 2016  | 15:54 IST
Lupin stock rises most on BSE post US FDA clearance

The Lupin stock on Monday rose the most on BSE after a notification that the inspection carried out by the US FDA in March 2016 at its Goa facility is now closed.

The stock was trading 104 points or 7.33 per cent higher on the BSE at 1,525 level.

On Friday, the firm said: This closes all outstanding US FDA inspections at Lupin's Goa facility.

Commenting on the receipt of the Establishment Inspection Report from US FDA, Vinita Gupta, Chief Executive Officer and Nilesh Gupta, Managing Director, Lupin said "We are committed to ensuring that all systems and processes followed by Lupin are compliant with cGMP and are committed to bringing quality products to market. We are grateful for the US FDA's confidence in our corrective action plan and in our team. It is our goal to remain well ahead on the compliance curve"

The stock closed 6.93 per cent or 98.50 points higher at Rs 1519 points on the BSE.

  • Print

A    A   A